{
    "clinical_study": {
        "@rank": "75639", 
        "brief_summary": {
            "textblock": "Dydrogesterone has been widely used worldwide for various gynecological and obstetric\n      indications:\n\n        -  Dydrogesterone is effective in cycle regulation treatment.\n\n        -  Dydrogesterone is recognized as none interference to hypothalamus pituitary ovary (HPO)\n           axis in the recommended dosage.\n\n        -  Dydrogesterone might have non-negative effect on glucose and lipid metabolic."
        }, 
        "brief_title": "Observational Study of Dydrogesterone in Cycle Regularization", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Observational Study", 
            "Dydrogesterone", 
            "Irregular Menstrual Cycle", 
            "Abnormal Uterine Bleeding"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Uterine Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "The current study is designed as a prospective, non-interventional, observational study.\n      Patients with irregular cycle diagnosed as AUB-O will be prescribed dydrogesterone as per\n      physician's clinical practice."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women aged 16 years or above with menses\n\n          -  Patient who is suffering from irregular menstrual cycle for at least 3 months and has\n             been diagnosed as AUB-O (irregular cycle is defined as cycle duration \uff1c 21days or \uff1e35\n             days)\n\n          -  Physicians have decided to prescribe dydrogesterone 10mg for cycle regulation\n             treatment, orally taking  dydrogesterone 10mg twice daily, from day16 to day 25 of\n             each cycle, being consecutive at least 3 cycles\n\n          -  Patient who is willing to sign written authorization\n\n        Exclusion Criteria:\n\n          -  Hyperprolactinemia and thyroid dysfunction.\n\n          -  Patient took cycle regulation treatment including oral contraceptives, sex hormone or\n             glucocorticoid in the past 1 month\n\n          -  Women with estrogen deficiency related symptom\n\n          -  Patient who meets the contraindications listed in Chinese label of dydrogesterone\n\n          -  Pregnant and lactating patients\n\n          -  Patient who is not suitable for the study according to physician's discretion"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Chinese women who is suffering from irregular menstrual cycle for at least 3 months and\n        has been diagnosed as AUB-O"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029144", 
            "org_study_id": "A14-390"
        }, 
        "intervention_browse": {
            "mesh_term": "Dydrogesterone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "contact": {
                "email": "zhangwei623@hotmail.com", 
                "last_name": "Wei Zhang, PhD", 
                "phone": "+86 13611691036"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200011"
                }, 
                "name": "Obstetrics and Gynecology Hospital of Fudan University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Dydrogesterone in Cycle Regularization in Abnormal Uterine Bleeding - Ovulation Dysfunction (AUB-O) Patients: A Prospective, Observational Study", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "percentage of patients reporting a regular cycle (defined as cycle duration\u226521 and \u2264 35 days) at the end of cycle 3", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029144"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Zhang Wei", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "collaborator": {
                "agency": "Abbott", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}